ObsEva SA (OBSV) EPS Estimated At $-0.49

January 13, 2018 - By Adrian Mccoy

 ObsEva SA (OBSV) EPS Estimated At $ 0.49

Analysts expect ObsEva SA (NASDAQ:OBSV) to report $-0.49 EPS on February, 13.After having $-0.59 EPS previously, ObsEva SA’s analysts see -16.95 % EPS growth. The stock decreased 0.51% or $0.05 during the last trading session, reaching $9.7. About 14,568 shares traded. ObsEva SA (NASDAQ:OBSV) has 0.00% since January 13, 2017 and is . It has underperformed by 16.70% the S&P500.

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. The company has market cap of $360.17 million. The firm intends to develop products for treating endometriosis, uterine fibroids, and preterm labor, as well as for enhancing clinical pregnancy and live birth rates in women undergoing IVF. It currently has negative earnings. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to improve clinical pregnancy and live birth rates in women undergoing IVF; and OBE022, an oral and selective prostaglandin F2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of pregnancy.

More notable recent ObsEva SA (NASDAQ:OBSV) news were published by: Bizjournals.com which released: “After $97M IPO, Swiss biotech to open US headquarters in Boston” on January 27, 2017, also Globenewswire.com with their article: “ObsEva SA (Nasdaq: OBSV) to Ring The Nasdaq Stock Market Opening Bell in …” published on January 26, 2017, Globenewswire.com published: “ObsEva SA Announces the Completion of a Phase 1 PK/PD Clinical Trial …” on June 07, 2017. More interesting news about ObsEva SA (NASDAQ:OBSV) were released by: Seekingalpha.com and their article: “ObsEva IPO: Early Stage Keeps Us Cautious On An IPO Investment” published on January 24, 2017 as well as Globenewswire.com‘s news article titled: “ObsEva SA Announces Pricing of Initial Public Offering” with publication date: January 26, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.